Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Kodiak Sciences

3 Small-Cap Biotechs With Binary Catalysts on the Calendar

Kodiak Sciences, Capricor Therapeutics and Invivyd each face pivotal clinical trial or FDA decisions before the end of 2026 that could significantly move their stock prices.

MarketBeat · Sep 13

Ameresco, Lithium Americas, Kodiak Sciences And Other Big Stocks Moving Higher On Thursday

U.S. stocks were lower, with the Nasdaq Composite falling more than 100 points on Thursday.

Benzinga · Sep 25, 2025

Jim Cramer: Kodiak Sciences Is A 'Pure Spec' Stock, Recommends Buying This Utilities Stock

On the latest edition of CNBC's “Mad Money Lightning Round,” Jim Cramer called Kodiak Sciences Inc. (NASDAQ:KOD) is a “pure spec” stock.

Benzinga · Aug 27, 2025

From analysis to the latest developments in health,
read the most diverse news in one place.

United Airlines And 3 Other Stocks Insiders Are Buying

Although US stocks closed slightly higher on Monday, there were a few notable insider trades.

Benzinga · Jun 7, 2022

What 5 Analyst Ratings Have To Say About Kodiak Sciences

Within the last quarter, Kodiak Sciences (NASDAQ:KOD) has observed the following analyst ratings:

Benzinga · May 11, 2022

Analyst Ratings for Kodiak Sciences

Within the last quarter, Kodiak Sciences (NASDAQ:KOD) has observed the following analyst ratings:

Benzinga · Apr 12, 2022

Recap: Kodiak Sciences Q4 Earnings

Kodiak Sciences (NASDAQ:KOD) reported its Q4 earnings results on Tuesday, March 1, 2022 at 04:10 PM. Here's what investors need to know about the announcement.

Benzinga · Mar 1, 2022

Read news from The Economist, FT, and more,
with one subscription

Expert Ratings For Kodiak Sciences

Analysts have provided the following ratings for Kodiak Sciences (NASDAQ:KOD) within the last quarter:

Benzinga · Feb 24, 2022

Why Kodiak Sciences Shares Are Plunging Today

Kodiak Sciences Inc (NASDAQ: KOD) has announced topline results from its Phase 2b/3 trial evaluating KSI-301 in treatment-naïve subjects with neovascular (wet) age-related macular degeneration.

Benzinga · Feb 23, 2022

What 4 Analyst Ratings Have To Say About Kodiak Sciences

Within the last quarter, Kodiak Sciences (NASDAQ:KOD) has observed the following analyst ratings:

Benzinga · Feb 1, 2022

3 Stocks Insiders Are Buying: Kodiak Sciences, EverQuote And More

Crude oil prices traded higher on Wednesday after gaining close to 3% in the prior session, as the API reported that US crude stockpiles dropped by 875,000 barrels last week.

Benzinga · Jan 26, 2022

People

Jim Cramer

549 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.